Sagimet Biosciences Inc.
NasdaqGM SGMT
Sagimet Biosciences Inc. Market Capitalization on January 14, 2025: USD 133.77 M
-
Sagimet Biosciences Inc. 52-week high Market Capitalization is USD 537.88 M on January 22, 2024, which is 302.09% above the current Market Capitalization.
-
Sagimet Biosciences Inc. 52-week low Market Capitalization is USD 79.27 M on August 14, 2024, which is -40.75% below the current Market Capitalization.
-
Sagimet Biosciences Inc. average Market Capitalization for the last 52 weeks is USD 154.09 M.
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
| CEO | Mr. David A. Happel |
| IPO Date | July 17, 2023 |
| Location | United States |
| Headquarters | 155 Bovet Road |
| Employees | 8 |
| Sector | Health Care |
| Industries | |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email